Loading…

Combination therapy of hepatitis B

Another major problem with the design was the differences in the timing of the end point evaluation in relation to therapy. [...]the end points were measured in patients receiving lamivudine while they were still on treatment, but in those receiving interferon or the combination at a point six month...

Full description

Saved in:
Bibliographic Details
Published in:Gut 2000-04, Vol.46 (4), p.450-451
Main Authors: DOO, E, HOOFNAGLE, J H
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Another major problem with the design was the differences in the timing of the end point evaluation in relation to therapy. [...]the end points were measured in patients receiving lamivudine while they were still on treatment, but in those receiving interferon or the combination at a point six months after stopping therapy. [...]at the one year point, HBV DNA levels, aminotransferases and liver histology may well have been affected by the continuation of lamivudine therapy.
ISSN:0017-5749
1468-3288
1458-3288
DOI:10.1136/gut.46.4.450